All In Biotech

Drug Trial Radar · NCT07650084

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - China Extension

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 21, 2025

Primary completion

Aug 27, 2027

Study completion Jun 2, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions

  • Refractory Chronic Cough

Interventions

  • BLU-5937Drug

    Oral administration of BLU-5937 Tablets.

  • PlaceboDrug

    Oral administration of matching placebo for BLU-5937 Tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-Hour Cough FrequencyTime frame: Week 24
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 24Time frame: Up to Week 24
  3. Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 24Time frame: Up to Week 24
  4. Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 24Time frame: Up to Week 24
  5. Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 24Time frame: Up to Week 24
  6. Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 24Time frame: Baseline, Week 24
  7. Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 24Time frame: Baseline, Week 24
  8. Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 24Time frame: Baseline, Week 24
  9. Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 24Time frame: Baseline, Week 24
  10. Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 24Time frame: Baseline, Week 24
  11. Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 24Time frame: Baseline, Week 24
  12. Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
  13. Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 24Time frame: Baseline, Week 24
  14. Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 24Time frame: Baseline, Week 24
  15. Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
  16. Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 24Time frame: Baseline, Week 24
  17. Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 24Time frame: Baseline, Week 24
  18. Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 24Time frame: Baseline, Week 24
  19. Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 24Time frame: Baseline, Week 24
  20. Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 24Time frame: Baseline, Week 24
  21. Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 24Time frame: Baseline, Week 24
  22. Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 24Time frame: Baseline, Week 24
  23. Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 24Time frame: Baseline, Week 24
  24. Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 24Time frame: Baseline, Week 24
  25. Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 24Time frame: Baseline, Week 24
  26. Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 24Time frame: Baseline, Week 24
  27. Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 24Time frame: Baseline, Week 24
  28. Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 24Time frame: Baseline, Week 24
  29. Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 24Time frame: Baseline, Week 24

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Beijing, China · Recruiting

  • GSK Investigational Site

    Changsha, China · Recruiting

  • GSK Investigational Site

    Chengdu, China · Recruiting

  • GSK Investigational Site

    Chengdu, China · Recruiting

  • GSK Investigational Site

    Chongqing, China · Recruiting

  • GSK Investigational Site

    Dongguan, China · Recruiting

  • GSK Investigational Site

    Ganzhou, China · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Guilin, China · Recruiting

  • GSK Investigational Site

    Hangzhou, China · Recruiting

  • GSK Investigational Site

    Hefei, China · Recruiting

  • GSK Investigational Site

    Hefei, China · Recruiting

  • GSK Investigational Site

    Hohhot, China · Recruiting

  • GSK Investigational Site

    Huizhou, China · Recruiting

  • GSK Investigational Site

    Huizhou, China · Recruiting

  • GSK Investigational Site

    Jiangsu, China · Recruiting

  • GSK Investigational Site

    Jinan, China · Recruiting

  • GSK Investigational Site

    Kunming, China · Recruiting

  • GSK Investigational Site

    Liuzhou, China · Recruiting

  • GSK Investigational Site

    Meizhou, China · Recruiting

  • GSK Investigational Site

    Nanchang, China · Recruiting

  • GSK Investigational Site

    Pingxiang, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shanghai, China · Recruiting

  • GSK Investigational Site

    Shenyang, China · Recruiting

  • GSK Investigational Site

    Shenzhen, China · Recruiting

  • GSK Investigational Site

    Taizhou, China · Recruiting

  • GSK Investigational Site

    Ürümqi, China · Recruiting

  • GSK Investigational Site

    Weifang, China · Recruiting

  • GSK Investigational Site

    Wuxi, China · Recruiting

  • GSK Investigational Site

    Xiamen, China · Recruiting

  • GSK Investigational Site

    Yangzhou, China · Recruiting

  • GSK Investigational Site

    Yinchuan, China · Recruiting

  • GSK Investigational Site

    Zhanjiang, China · Recruiting

  • GSK Investigational Site

    Zhengzhou, China · Recruiting

  • GSK Investigational Site

    Leshan, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.